安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Sarilumab (Kevzara) - American College of Rheumatology
Sarilumab (Kevzara) is biologic medication approved to treat adults with moderate to severe active rheumatoid arthritis (RA) See information for patients and caregivers, including how to take it, side effects, and things to tell your physician
- PATIENT FACT SHEET Sarilumab (Kevzara) - AchyJoint
PATIENT FAC Sarilumab (Kevzara) WHAT IS IT? vere active rheumatoid arthritis (RA) Biologic medications are proteins designed y humans that afect the immune system Sarilumab blocks a messenger of inflammation cal ed the interleukin-6 receptor (IL-6R) This improves joint pain and swelling from arthritis and
- KEVZARA Combination Therapy Long-Term Data | KEVZARA® (sarilumab . . .
KEVZARA® (sarilumab) is indicated for treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs)
- Kevzara (Sarilumab), a New IL-6 Receptor Antagonist, Approved for . . .
On May 22, 2017, the US Food and Drug Administration (FDA) approved sarilumab (Kevzara; sanofiaventis Regeneron), an interleukin (IL)-6 receptor antagonist, for the treatment of adults with moderately to severely active RA who cannot tolerate or have had an inadequate response to ≥1 DMARDs 10
- Sarilumab (Kevzara®)
Sarilumab (Kevzara) is a human recombinant monoclonal antibody interleukin-6 (IL-6) receptor antagonist that binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R) to inhibit IL-6 mediated signaling
- Sarilumab (KEVZARA) in Rheumatoid Arthritis - Veterans Affairs
Sarilumab may be used in combination with methotrexate, other nonbiologic disease-modifying antirheumatic drugs (DMARDs), mycophenolate, hydroxychloroquine, or glucocorticoids In general, concomitant use of potent immunosuppressives with sarilumab should be avoided
- Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid . . .
We performed the Sarilumab in Patients with Polymyalgia Rheumatica (SAPHYR) trial to evaluate the efficacy and safety of sarilumab in patients with polymyalgia rheumatica who had a disease
- Sarilumab in relapsing polymyalgia rheumatica: patient-reported . . .
We aimed to evaluate the effect of sarilumab on patient-reported outcomes This phase 3, double-blind, randomised controlled trial was done in 60 centres in 17 countries
|
|
|